Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis

Annals of the Rheumatic Diseases

Volumn 69, Issue 5, 2010, Pages 935-936

  Cañete, Juan D ^a   Celis, Raquel ^a   Hernández, Victoria ^a   Pablos, José Luis ^b   Sanmartí, Raimon ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; C REACTIVE PROTEIN;

ADULT; ARTHRALGIA; CASE REPORT; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; JOINT BIOPSY; JOINT SWELLING; KNEE ARTHROSCOPY; LETTER; MALE; POLYARTHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; PSORIATIC ARTHRITIS; SYNOVITIS;

ADULT; ARTHRITIS, PSORIATIC; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KNEE JOINT; MALE; SYNOVIAL MEMBRANE;

EID: 77951608958     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.113233     Document Type: Letter

References (10)

1. Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 2009;11:214.
2. van der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007;56:2698-2707 (Pubitemid 47237288)
3. Abrams JR, Kelley SL, Hayes E, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000;192:681-694
4. Olivieri I, D'Angelo S, Mennillo GA, et al. Abatacept in spondyloarthritis refractory to tumour necrosis factor alpha inhibition. Ann Rheum Dis 2009;68:151-152
5. Cañete JD, Santiago B, Cantaert T, et al. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis 2007;66:720-726 (Pubitemid 46846689)
6. Vandooren B, Noordenbos T, Ambarus C, et al. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum 2009;60:966-975
7. Kruithof E, De Rycke L, Vandooren B, et al; OMERACT Special Interest Group on Synovial Analysis in Clinical Trials. Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum 2006;54:1795-1804
8. Kraan MC, van Kuijk AW, Dinant HJ, et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002;46:2776-2784
9. Goedkoop AY, Kraan MC, Teunissen MB, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004;63:769-773
10. Buch MH, Boyle DL, Rosengren S, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009;68:1220-1227